[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "",
    "text": "Reference Paper: Sreenivasan et al. 2022\nStudy Objective: Examine the impact of body mass index (BMI) on in-hospital mortality among patients with coronary artery disease (CAD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all hospitalized patients diagnosed with CAD.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcome: In-hospital all-cause mortality.\nStatistical Analysis: Multiple logistic regression to determine the independent association of BMI categories with in-hospital mortality, adjusted for:\n\nDemographics: Age, gender, race\nMedical History: Previous coronary artery bypass graft, myocardial infarction, percutaneous coronary intervention\nComorbidities: Atrial fibrillation, cerebrovascular disease, heart failure, peripheral vascular disease, dementia, tobacco use disorder, chronic obstructive pulmonary disease, valvular heart disease, liver disease, diabetes mellitus, hypertension, chronic kidney disease, dialysis dependence, anemia, hyperlipidemia, and any cancer.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)\n\nThis analysis aims to provide insights into how different BMI categories affect the mortality risk of hospitalized CAD patients, offering valuable information for clinical management and patient care strategies."
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "",
    "text": "Reference Paper: Sreenivasan et al. 2022\nStudy Objective: Examine the impact of body mass index (BMI) on in-hospital mortality among patients with coronary artery disease (CAD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all hospitalized patients diagnosed with CAD.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcome: In-hospital all-cause mortality.\nStatistical Analysis: Multiple logistic regression to determine the independent association of BMI categories with in-hospital mortality, adjusted for:\n\nDemographics: Age, gender, race\nMedical History: Previous coronary artery bypass graft, myocardial infarction, percutaneous coronary intervention\nComorbidities: Atrial fibrillation, cerebrovascular disease, heart failure, peripheral vascular disease, dementia, tobacco use disorder, chronic obstructive pulmonary disease, valvular heart disease, liver disease, diabetes mellitus, hypertension, chronic kidney disease, dialysis dependence, anemia, hyperlipidemia, and any cancer.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)\n\nThis analysis aims to provide insights into how different BMI categories affect the mortality risk of hospitalized CAD patients, offering valuable information for clinical management and patient care strategies."
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 3,540,4251\nNormal weight (BMI 20.0-24.9kg/m²), N = 256,0001\nClass I obesity (BMI 30.0-34.9kg/m²), N = 836,9801\nClass II obesity (BMI 35.0-39.9kg/m²), N = 692,2151\nClass III obesity (BMI ≥40.0kg/m²), N = 1,038,7701\nOverweight (BMI 25.0-29.9kg/m²), N = 338,6501\nUnderweight (BMI ≤19.9kg/m²), N = 377,8101\np-value2\n\n\n\n\nAge, y\n69 (12)\n76 (11)\n69 (11)\n67 (11)\n64 (11)\n72 (11)\n76 (11)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n1,553,895 (44%)\n96,515 (38%)\n308,290 (37%)\n288,125 (42%)\n547,540 (53%)\n125,705 (37%)\n187,720 (50%)\n\n\n\n\n    Male\n1,986,530 (56%)\n159,485 (62%)\n528,690 (63%)\n404,090 (58%)\n491,230 (47%)\n212,945 (63%)\n190,090 (50%)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n2,652,535 (75%)\n188,155 (73%)\n640,975 (77%)\n526,895 (76%)\n769,670 (74%)\n249,600 (74%)\n277,240 (73%)\n\n\n\n\n    Asian or Pacific Islander\n51,535 (1.5%)\n7,910 (3.1%)\n10,460 (1.2%)\n6,270 (0.9%)\n6,760 (0.7%)\n6,755 (2.0%)\n13,380 (3.5%)\n\n\n\n\n    Black\n488,170 (14%)\n33,320 (13%)\n97,335 (12%)\n90,405 (13%)\n170,310 (16%)\n40,960 (12%)\n55,840 (15%)\n\n\n\n\n    Hispanic\n256,575 (7.2%)\n18,890 (7.4%)\n66,495 (7.9%)\n51,440 (7.4%)\n67,390 (6.5%)\n31,410 (9.3%)\n20,950 (5.5%)\n\n\n\n\n    Native American\n18,070 (0.5%)\n1,075 (0.4%)\n4,140 (0.5%)\n3,480 (0.5%)\n6,320 (0.6%)\n1,360 (0.4%)\n1,695 (0.4%)\n\n\n\n\n    Other\n73,540 (2.1%)\n6,650 (2.6%)\n17,575 (2.1%)\n13,725 (2.0%)\n18,320 (1.8%)\n8,565 (2.5%)\n8,705 (2.3%)\n\n\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n1,129,445 (32%)\n76,940 (30%)\n251,940 (30%)\n216,475 (31%)\n361,195 (35%)\n102,985 (30%)\n119,910 (32%)\n\n\n\n\n    $52,000 - $65,999\n991,430 (28%)\n67,295 (26%)\n232,265 (28%)\n198,995 (29%)\n302,500 (29%)\n91,180 (27%)\n99,195 (26%)\n\n\n\n\n    $66,000 - $87,999\n828,610 (23%)\n59,720 (23%)\n202,980 (24%)\n165,115 (24%)\n235,555 (23%)\n80,285 (24%)\n84,955 (22%)\n\n\n\n\n    $88,000 or more\n590,940 (17%)\n52,045 (20%)\n149,795 (18%)\n111,630 (16%)\n139,520 (13%)\n64,200 (19%)\n73,750 (20%)\n\n\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n306,770 (8.7%)\n14,435 (5.6%)\n62,805 (7.5%)\n60,895 (8.8%)\n122,385 (12%)\n22,185 (6.6%)\n24,065 (6.4%)\n\n\n\n\n    Medicare\n2,480,960 (70%)\n210,350 (82%)\n575,250 (69%)\n455,100 (66%)\n671,365 (65%)\n255,605 (75%)\n313,290 (83%)\n\n\n\n\n    No charge\n6,890 (0.2%)\n275 (0.1%)\n2,045 (0.2%)\n1,375 (0.2%)\n2,240 (0.2%)\n565 (0.2%)\n390 (0.1%)\n\n\n\n\n    Other\n80,665 (2.3%)\n5,145 (2.0%)\n20,915 (2.5%)\n17,285 (2.5%)\n22,645 (2.2%)\n7,905 (2.3%)\n6,770 (1.8%)\n\n\n\n\n    Private\n591,730 (17%)\n22,920 (9.0%)\n157,345 (19%)\n140,505 (20%)\n195,520 (19%)\n46,300 (14%)\n29,140 (7.7%)\n\n\n\n\n    Self-pay\n73,410 (2.1%)\n2,875 (1.1%)\n18,620 (2.2%)\n17,055 (2.5%)\n24,615 (2.4%)\n6,090 (1.8%)\n4,155 (1.1%)\n\n\n\n\nHypertension\n3,204,925 (91%)\n218,475 (85%)\n767,460 (92%)\n640,865 (93%)\n964,675 (93%)\n304,235 (90%)\n309,215 (82%)\n&lt;0.001\n\n\nDiabetes mellitus\n2,001,830 (57%)\n96,875 (38%)\n479,180 (57%)\n436,405 (63%)\n715,345 (69%)\n173,155 (51%)\n100,870 (27%)\n&lt;0.001\n\n\nChronic kidney disease\n1,301,220 (37%)\n94,635 (37%)\n292,155 (35%)\n249,305 (36%)\n419,095 (40%)\n125,125 (37%)\n120,905 (32%)\n&lt;0.001\n\n\nDialysis dependence\n173,560 (4.9%)\n15,935 (6.2%)\n40,280 (4.8%)\n31,990 (4.6%)\n45,895 (4.4%)\n19,395 (5.7%)\n20,065 (5.3%)\n&lt;0.001\n\n\nLiver disease\n211,915 (6.0%)\n17,955 (7.0%)\n46,245 (5.5%)\n38,600 (5.6%)\n64,585 (6.2%)\n22,560 (6.7%)\n21,970 (5.8%)\n&lt;0.001\n\n\nCancer\n193,960 (5.5%)\n29,270 (11%)\n40,985 (4.9%)\n27,895 (4.0%)\n34,400 (3.3%)\n25,665 (7.6%)\n35,745 (9.5%)\n&lt;0.001\n\n\nCOPD\n1,358,760 (38%)\n87,505 (34%)\n274,545 (33%)\n249,195 (36%)\n461,595 (44%)\n107,995 (32%)\n177,925 (47%)\n&lt;0.001\n\n\nAnemia\n254,170 (7.2%)\n26,510 (10%)\n51,015 (6.1%)\n40,400 (5.8%)\n71,255 (6.9%)\n26,510 (7.8%)\n38,480 (10%)\n&lt;0.001\n\n\nPeripheral vascular disease\n559,235 (16%)\n51,350 (20%)\n136,985 (16%)\n100,170 (14%)\n122,055 (12%)\n61,650 (18%)\n87,025 (23%)\n&lt;0.001\n\n\nAtrial fibrillation\n976,495 (28%)\n74,645 (29%)\n222,765 (27%)\n185,100 (27%)\n295,715 (28%)\n94,115 (28%)\n104,155 (28%)\n&lt;0.001\n\n\nPrior MI\n856,140 (24%)\n60,070 (23%)\n213,585 (26%)\n172,880 (25%)\n236,135 (23%)\n82,775 (24%)\n90,695 (24%)\n&lt;0.001\n\n\nPrior PCI\n885,250 (25%)\n60,315 (24%)\n236,870 (28%)\n189,850 (27%)\n235,995 (23%)\n89,355 (26%)\n72,865 (19%)\n&lt;0.001\n\n\nPrior CABG\n618,950 (17%)\n55,940 (22%)\n164,445 (20%)\n126,135 (18%)\n139,640 (13%)\n72,285 (21%)\n60,505 (16%)\n&lt;0.001\n\n\nCerebrovascular disease\n333,925 (9.4%)\n28,800 (11%)\n84,830 (10%)\n61,125 (8.8%)\n78,175 (7.5%)\n37,830 (11%)\n43,165 (11%)\n&lt;0.001\n\n\nDementia\n261,580 (7.4%)\n49,150 (19%)\n43,335 (5.2%)\n25,905 (3.7%)\n28,705 (2.8%)\n36,085 (11%)\n78,400 (21%)\n&lt;0.001\n\n\nHeart failure\n1,837,020 (52%)\n120,885 (47%)\n391,175 (47%)\n350,380 (51%)\n636,345 (61%)\n158,430 (47%)\n179,805 (48%)\n&lt;0.001\n\n\nTobbacco use disorder\n25,280 (0.7%)\n1,565 (0.6%)\n6,245 (0.7%)\n5,170 (0.7%)\n6,970 (0.7%)\n2,390 (0.7%)\n2,940 (0.8%)\n&lt;0.001\n\n\nHyperlipidemia\n2,473,065 (70%)\n155,090 (61%)\n634,970 (76%)\n515,090 (74%)\n716,070 (69%)\n243,250 (72%)\n208,595 (55%)\n&lt;0.001\n\n\nLength of stay (days)\n5.8 (6.0)\n7.3 (7.0)\n5.2 (5.3)\n5.1 (5.1)\n5.8 (6.0)\n6.2 (6.5)\n7.1 (7.5)\n&lt;0.001\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 3,540,4251\nNormal weight (BMI 20.0-24.9kg/m²), N = 256,0001\nClass I obesity (BMI 30.0-34.9kg/m²), N = 836,9801\nClass II obesity (BMI 35.0-39.9kg/m²), N = 692,2151\nClass III obesity (BMI ≥40.0kg/m²), N = 1,038,7701\nOverweight (BMI 25.0-29.9kg/m²), N = 338,6501\nUnderweight (BMI ≤19.9kg/m²), N = 377,8101\np-value2\n\n\n\n\nAll-cause mortality\n103,530 (2.9%)\n13,185 (5.2%)\n15,555 (1.9%)\n12,590 (1.8%)\n25,990 (2.5%)\n10,625 (3.1%)\n25,585 (6.8%)\n&lt;0.001\n\n\n\n1 n (%)\n\n\n2 chi-squared test with Rao & Scott’s second-order correction"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nBody mass index (BMI)\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n0.50\n0.47, 0.53\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n0.52\n0.49, 0.55\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n0.71\n0.68, 0.76\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.72\n0.68, 0.76\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1.36\n1.29, 1.43\n&lt;0.001\n\n\nAge, y\n1.03\n1.03, 1.03\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.15\n1.11, 1.18\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.25\n1.13, 1.38\n&lt;0.001\n\n\n    Black\n0.97\n0.93, 1.02\n0.2\n\n\n    Hispanic\n1.08\n1.01, 1.15\n0.022\n\n\n    Native American\n1.12\n0.92, 1.37\n0.3\n\n\n    Other\n1.13\n1.03, 1.25\n0.009\n\n\nPrior CABG\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.91\n0.87, 0.94\n&lt;0.001\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.87\n0.83, 0.90\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.76, 0.82\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.26\n1.22, 1.30\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.36\n1.30, 1.42\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.58\n1.53, 1.63\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.03\n0.99, 1.07\n0.14\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.19\n1.13, 1.24\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.87\n0.71, 1.06\n0.2\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.96, 1.02\n0.5\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.89, 0.96\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.97\n2.84, 3.10\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.96, 1.02\n0.5\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.68\n0.65, 0.71\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.21\n1.17, 1.25\n&lt;0.001\n\n\nDialysis dependence\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.43\n1.35, 1.52\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.74, 0.83\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.68\n0.66, 0.70\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.27\n1.21, 1.34\n&lt;0.001\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  }
]